Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 8:4:100093.
doi: 10.1016/j.jhlto.2024.100093. eCollection 2024 May.

Outcomes of left ventricular assist device implantations at Karolinska University Hospital: A retrospective study

Abraham Merzo  1   2   3 , Magnus Dalén  4   5 , Ann Hallberg Kristensen  6 , Michael Melin  6   7 , Jonas Faxén  6   8 , Robert Edfors  9   10 , Emil Najjar  1   6
Affiliations

Outcomes of left ventricular assist device implantations at Karolinska University Hospital: A retrospective study

Abraham Merzo et al. JHLT Open. .

Abstract

Background: To descriptively present data and outcomes of left ventricular assist device (LVAD) implantations at Karolinska University Hospital.

Methods: Data were collected from consecutive patients (n = 44) who were implanted with HeartMate 3 (HM3) at Karolinska University Hospital between 2017 and 2022. The study presents baseline characteristics, clinical course during the inpatient hospital care after implantation, adverse events, and clinical outcomes.

Results: Median intensive care unit stay and hospital stay after HM3 implantation was 8 (interquartile range [IQR] 6; 15) and 28 days (IQR 22; 36), respectively. In total, 73% underwent ramp test at some point after the implantation. Death from all causes within 30 days postimplantation was 5%. A total of 21 patients (48%) underwent right heart catheterization, at a median of 0.5 years (IQR 0.3; 0.7) after implantation, and all exhibited optimally unloaded left ventricles. During the study period, 34% of the patients were transplanted, 5% were explanted, and 16% died with LVAD. In total, 11% and 5% suffered from early and late right ventricle failures, respectively. Acute renal failure affected 46% and 18% had driveline infection. Spontaneous cerebral hemorrhage and cerebral infarction affected 5% and 7% of the study population, respectively. Gastrointestinal bleeding affected 16%. The median LVAD duration was 10 months (IQR 5; 22). The 1-year survival rate with LVAD was 85%, and the 2-year survival rate was 80%.

Conclusions: The results of this low-volume single-center retrospective study on LVAD implantations align with the results of other studies and international registries.

Keywords: HeartMate 3; heart failure; heart transplantation; left ventricular assist device; mechanical circulatory support.

PubMed Disclaimer

Conflict of interest statement

E.N.: speaker’s honoraria from Novartis, Astra Zeneca, Bayer, Bristol Myers Squibb. R.E. is an employee of Bayer AG and reports no conflicts related to this work. The other authors have no relationships that could be construed as a conflict of interest. No funding was received.

Figures

Figure 1
Figure 1
Competitive outcomes in LVAD patients in Karolinska University Hospital. LVAD, left ventricular assist device.
Figure 2
Figure 2
The survival of LVAD patients at Karolinska University Hospital. Transplanted and explanted patients were censored. LVAD, left ventricular assist device.
See this image and copyright information in PMC

References

    1. McMurray J.J., Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602. - PMC - PubMed
    1. Savarese G., Stolfo D., Sinagra G., Lund L.H. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100–116. - PMC - PubMed
    1. Potapov E.V., Antonides C., Crespo-Leiro M.G., et al. 2019 EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56:230–270. - PMC - PubMed
    1. Shah P., Yuzefpolskaya M., Hickey G.W., et al. Twelfth interagency registry for mechanically assisted circulatory support report: readmissions after left ventricular assist device. Ann Thorac Surg. 2022;113:722–737. - PMC - PubMed
    1. Mehra M.R., Cleveland J.C., Jr, Uriel N., et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail. 2021;23:1392–1400. - PMC - PubMed

LinkOut - more resources